Halozyme Therapeutics (HALO) reported Q1 2026 results with revenue of $376.7 million, up 42.2% year-over-year and beating the consensus revenue estimate of $366.2 million by $10.5 million. Diluted earnings per share came in at 1.22, up 31.2% year-over-year but below the EPS estimate of 1.56 (roughly 22% under the estimate).
Balance sheet and cash-flow highlights show strong liquidity and operating cash generation.
Cost of sales increased to $79.2 million (+63.7% YoY), while overall trends point to expanding profitability and strong cash generation despite the EPS coming in below expectations. The report underscores continued top-line momentum for Halozyme Therapeutics (HALO) heading into the rest of 2026.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Halozyme Therapeutics Inc. Insider Trading Activity
Halozyme Therapeutics Inc. insiders have traded $HALO stock on the open market 39 times in the past 6 months. Of those trades, 0 have been purchases and 39 have been sales.
Here’s a breakdown of recent trading of $HALO stock by insiders over the last 6 months:
- HELEN TORLEY (PRESIDENT AND CEO) has made 0 purchases and 32 sales selling 226,569 shares for an estimated $15,866,732.
- CORTNEY CAUDILL (SVP, CHIEF OPERATING OFFICER) has made 0 purchases and 3 sales selling 28,857 shares for an estimated $1,955,159.
- BERNADETTE CONNAUGHTON has made 0 purchases and 4 sales selling 6,454 shares for an estimated $439,971.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Halozyme Therapeutics Inc. Hedge Fund Activity
We have seen 301 institutional investors add shares of Halozyme Therapeutics Inc. stock to their portfolio, and 319 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 1,842,956 shares (+inf%) to their portfolio in Q4 2025, for an estimated $124,030,938
- MACQUARIE GROUP LTD removed 1,546,185 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $104,058,250
- NORGES BANK added 1,039,354 shares (+120.1%) to their portfolio in Q4 2025, for an estimated $69,948,524
- D. E. SHAW & CO., INC. removed 1,000,909 shares (-37.8%) from their portfolio in Q4 2025, for an estimated $67,361,175
- MIZUHO MARKETS AMERICAS LLC added 926,526 shares (+270.8%) to their portfolio in Q4 2025, for an estimated $62,355,199
- MORGAN STANLEY added 920,699 shares (+53.0%) to their portfolio in Q4 2025, for an estimated $61,963,042
- JANE STREET GROUP, LLC removed 911,024 shares (-84.7%) from their portfolio in Q4 2025, for an estimated $61,311,915
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Halozyme Therapeutics Inc. Congressional Stock Trading
Members of Congress have traded $HALO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HALO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/09.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Halozyme Therapeutics Inc. Analyst Ratings
Wall Street analysts have issued reports on $HALO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 01/08/2026
- HC Wainwright & Co. issued a "Buy" rating on 12/19/2025
To track analyst ratings and price targets for Halozyme Therapeutics Inc., check out Quiver Quantitative's $HALO forecast page.
Halozyme Therapeutics Inc. Price Targets
Multiple analysts have issued price targets for $HALO recently. We have seen 5 analysts offer price targets for $HALO in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $95.0 on 04/29/2026
- Mohit Bansal from Wells Fargo set a target price of $75.0 on 02/19/2026
- Robert Wasserman from Benchmark set a target price of $90.0 on 02/19/2026
- Brendan Smith from TD Cowen set a target price of $90.0 on 01/08/2026
- Graig Suvannavejh from Goldman Sachs set a target price of $56.0 on 11/18/2025
